top of page

Pfizer secures FDA approval for expanded use of Xalkori cancer drug

The US Food and Drug Administration has approved Pfizer's Xalkori (crizotinib) to treat a rare form of advanced non-small-cell lung cancer (NSCLC).

The drug's use has been expanded to treat patients with advanced, or metastatic, NSCLC whose tumors have an ROS-1 gene alteration, which is believed to lead to abnormal cells.

Xalkori is the first and only FDA-approved treatment for patients with the ROS-1 gene alteration.

The drug was initially approved in 2011 to treat NSCLC patients who test positive for alterations in a gene known as ALK.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page